Pen Needle Market Size, Share, Opportunities, And Trends by Type (Standard Pen Needles, Safety Pen Needles), Needle Length (4mm and 5mm, 6mm and 8mm, 10mm and 12mm), Therapy (Insulin, Glucagon-like-Peptide-1, Growth Hormone), Distribution Channel (Online, Offline), And By Geography - Forecasts From 2025 To 2030

The pen needle market is expected to grow at a CAGR of 9.27% over the forecast period to reach a total market size of US$3,189.012 million by 2030, increasing from US$2,046.792 million in 2025. 

Pen needles are widely used to deliver injectable medication into the body. The rising prevalence of chronic disease is expected to be one of the prime drivers of market growth during the forecast period. However, the availability of substitutes is anticipated to restrain the market's growth in the coming years.

What are the Pen Needle Market Drivers?

• The growing prevalence of various chronic diseases is anticipated to drive the market in the forecasted period.

The rising prevalence of chronic diseases such as cancer and diabetes is one of the prime drivers for the market growth during the forecast period. According to the International Diabetes Federation report, the number of people with diabetes under the age group of 20-79 years has risen from 425 million in 2017 to 537 million in 2022 and is expected to reach 783 million in 2045.

In addition, the rising economic burden of diabetes and increasing healthcare expenditure worldwide are also anticipated to increase the demand for rapid diagnostic kits for glucose monitoring in the coming years. According to the International Diabetes Federation (IDF), global healthcare expenditure on diabetes was around USD 966 billion in 2022, representing an increase of 316% over the last 15 years. 

According to the World Health Organization (WHO), in 2022, nearly 1.3 million people died from chronic hepatitis B and C infection, and approximately 254 million people lived with hepatitis B, and 50 million people are living with hepatitis C. The WHO, in its report, stated that in 2010, an estimated 524 million people were aged 65 or older, which constitutes 8 percent of the world’s population, and by 2050 this number is expected to nearly triple to about 1.5 billion, representing 16% of the world population.

Poor nutrition, physical inactivity, and the harmful use of alcohol contribute to the development of chronic conditions like cardiovascular diseases, cancer, and chronic respiratory disease, which will directly affect the market for pen needles in the coming years.

• Rising aging population will boost the market expansion

One of the main factors driving the market's expansion over the forecast period is anticipated to be the growing elderly population in several regions of the world. For instance, based only on the rising geriatric population in a developing country like China, the WHO has predicted a 50% increase in annual cardiovascular disease occurrences between 2010 and 2030. 

According to the World Bank, Europe's population aged sixty-five and above was 448.8 million people, making up one-fifth of the total population, 21.3% in 2023. In addition, rising disposable income encourages people to demand better quality healthcare solutions for which they are ready to pay high premiums. The surging demand for private health insurance plans is also increasing the number of surgical procedures in this country.

Segment Analysis of the Pen Needle Market:

• The insulin therapy segment is anticipated to hold a significant market share in the projected period.

The pen needle market is divided by therapy into insulin, glucagon-like peptide-1 (GLP-1), and growth hormone administration, driven by the increasing prevalence of chronic conditions and rising demand for self-injection devices. Insulin therapy held the largest share, mainly because of the increasing diabetic population and widespread use of insulin pens for ease and accuracy in self-administration.

The GLP-1 segment is highly growth-positive and has achieved immense success in treating type 2 diabetes and weight-related disorders. As a result, demand for pen needles compatible with the drugs is rising. Growth hormone therapy also adds significantly, particularly for pediatric and adult patients requiring hormone replacement, where the use of pen needles is less invasive and more patient-friendly. Advances in the design of pen needles, such as ultra-thin, short needles, are driving growth in the market for all therapeutic segments.

North America holds a significant share of the market:

By geography, the pen needle market is segmented into North America, South America, Europe, the Middle East, Africa, and the Asia Pacific. The pen needle is fast gaining traction in North America due to the growing number of chronic disease cases. According to the United States Centre for Disease Control and Prevention, 6,08,336 people died due to cancer in the United States. The burgeoning need for a targeted drug delivery system that causes minimal side effects drives the demand for pen needles in the country.

Advancements in technology and increased healthcare spending have significantly boosted the pen needle market growth. For instance, U.S. healthcare spending increased by 4.1% to reach USD 4.5 trillion in 2022, as per the United States Centre for Medicare and Medicaid Services.

In Europe, the government is easing regulations and speeding up the approval process for innovative new drugs to meet the increasing needs of the aging population. This initiative aims to promote domestic and foreign pharmaceutical companies and attract new businesses to the European market.

In addition, increasing strategic investment by domestic market players in the form of mergers and acquisitions increases the competition, which is further expected to propel market growth opportunities in the coming years.

Furthermore, in the Asia Pacific region, increasing health awareness among the population and the rapid market evolution in using new injectable drug delivery systems or technologies are expected to drive market growth during the forecast period. The Chinese and Indian governments are establishing new policies to improve the population's health, including coverage expansion of public healthcare institutions and standardizing their services.

Key Developments in the Pen Needle Market:

• In September 2022, Terumo India, the Indian arm of Terumo, a global leader in medical technology, launched FineGlide™, a Sterile Pen Needle for patients requiring regular insulin injections or other self-medication.
• In May 2022, Roche Diabetes Care introduced pen needless into the market under the brand ACCU-FINE. The pen needles are designed to enable painless and smooth delivery of insulin. According to the firm, this product can effectively enhance the outcome for diabetic patients and is available in packs of hundred needles, each in three variants, including a 33G 4mm variant.

The Pen Needle market is segmented and analyzed as follows:

• By Type
  • Standard Pen Needles
  • Safety Pen Needles
• By Length
  • 4mm and 5mm
  • 6mm and 8mm
  • 10mm and 12mm
• By Therapy
  • Insulin 
  • Glucagon-like-Peptide-1
  • Growth Hormone
• By Distribution Channel
  • Online
  • Offline
• By Geography
  • North America
    • USA
    • Canada
    • Mexico
  • South America
    • Brazil
    • Argentina
    • Others
  • Europe
    • UK
    • Germany
    • France
    • Spain
    • Italy
    • Others
  • Middle East and Africa
    • UAE
    • Saudi Arabia
    • Others
  • Asia Pacific
    • Japan
    • China
    • India
    • South Korea
    • Indonesia
    • Thailand
    • Others

1. INTRODUCTION

1.1. Market Overview

1.2. Market Definition

1.3. Scope of the Study

1.4. Market Segmentation

1.5. Currency

1.6. Assumptions

1.7. Base and Forecast Years Timeline

1.8. Key benefits for the stakeholders

2. RESEARCH METHODOLOGY  

2.1. Research Design

2.2. Research Process

3. EXECUTIVE SUMMARY

3.1. Key Findings

3.2. Analyst View

4. MARKET DYNAMICS

4.1. Market Drivers

4.1.1. Growing Demand for Packaging

4.1.2. Increasing Focus on Sustainability

4.2. Market Restraints

4.2.1. Environmental Concerns

4.2.2. High Production Cost

4.3. Porter’s Five Forces Analysis

4.3.1. Bargaining Power of Suppliers

4.3.2. Bargaining Power of Buyers

4.3.3. The Threat of New Entrants

4.3.4. Threat of Substitutes

4.3.5. Competitive Rivalry in the Industry

4.4. Industry Value Chain Analysis

5. PEN NEEDLE MARKET ANALYSIS BY TYPE

5.1. Introduction

5.2. Standard Pen Needles

5.3. Safety Pen Needles

6. PEN NEEDLE MARKET ANALYSIS BY LENGTH

6.1. Introduction

6.2. 4mm and 5mm

6.3. 6mm and 8mm

6.4. 10mm and 12mm

7. PEN NEEDLE MARKET ANALYSIS BY THERAPY

7.1. Introduction

7.2. Insulin 

7.3. Glucagon-like-Peptide-1

7.4. Growth Hormone

8. PEN NEEDLE MARKET ANALYSIS BY DISTRIBUTION CHANNEL

8.1. Introduction

8.2. Online

8.3. Offline

9. PEN NEEDLE MARKET ANALYSIS BY GEOGRAPHY

9.1. Introduction

9.2. North America 

9.2.1. United States 

9.2.2. Canada 

9.2.3. Mexico 

9.3. South America 

9.3.1. Brazil 

9.3.2. Argentina 

9.3.3. Others

9.4. Europe 

9.4.1. UK 

9.4.2. Germany 

9.4.3. France 

9.4.4. Spain 

9.4.5. Italy 

9.4.6. Others

9.5. Middle East and Africa 

9.5.1. UAE 

9.5.2. Saudi Arabia 

9.5.3. Others

9.6. Asia Pacific 

9.6.1. Japan 

9.6.2. China 

9.6.3. India 

9.6.4. South Korea 

9.6.5. Indonesia 

9.6.6. Thailand 

9.6.7. Others

10. COMPETITIVE ENVIRONMENT AND ANALYSIS

10.1. Major Players and Strategy Analysis

10.2. Emerging Players and Market Lucrativeness

10.3. Mergers, Acquisitions, Agreements, and Collaborations

10.4. Vendor Competitiveness Matrix

11. COMPANY PROFILES

11.1. Becton, Dickinson and Company

11.2. Glucorx

11.3. Braun Melsungen

11.4. Ypsomed

11.5. Novo Nordisk

11.6. HTL-Strefa

11.7. Ultimed, Inc.

11.8. Allison Medical, Inc. 

11.9. Terumo Corporation

11.10. Owen Mumford, Ltd.

Becton, Dickinson and Company

Glucorx

Braun Melsungen

Ypsomed

Novo Nordisk

HTL-Strefa

Ultimed, Inc.

Allison Medical, Inc. 

Terumo Corporation

Owen Mumford, Ltd.